IRLAB Therapeutics AB (publ) (IRLAB_A) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the quarterly presentation of the fourth quarter and the year-end results by research company iLab Therapeutics. Presenting today is CEO Kristina Torfgaard, Executive Vice President R&D Nicholas Waters and CFO Viktor Sivic. After the presentation we will be given a Q&A with participating equity analysts and viewers can ask their questions in the live chat. Hello and welcome Kristina Torfgaard. Hello, good morning. Please go ahead with your presentation and I will be back for the Q&A. Thanks. So can we have the first slide and the next one, please? So today's agenda, I will introduce and take you through the news of this period and beyond that. That will be followed up by the R&D update from Nicholas Waters, EVP, head of R&D. And then Victor Sieverts will continue with the financials. And I will have some concluding words and also inform you a little bit about the future. So the next slide, please. So I would just like to remind you that IOLAB, we are developing new, innovative and better medicines for treating Parkinson's disease for all the different stages. On this slide, you can see the core and the main symptoms that the patients or the individuals are experiencing at the time when they get the disease. However, if we have another click on this slide, you can see that there are a number of different symptoms that are developed during the progress of the disease. And on the right side there, you can see we have five candidate drugs. They are all first in class and they are unique in that sense. And with those, you can see that we are aiming to treat all the different symptoms that can be experienced during the disease. So the next slide. So I will take you through the key highlights during this period and after. So we received 2.5 million US dollar from...